FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Wednesday, March 4, 2026Time:8:30 am Eastern TimeToll Free:1-800-7 ...

Core Viewpoint - Cellectar Biosciences, Inc. has successfully closed a public offering, raising approximately $6.9 million to support its cancer treatment drug development efforts [1][4]. Offering Details - The offering consists of 1,045,000 Class A Units and 335,000 Class B Units, with Class A Units priced at $5.00 each and Class B Units at $4.99999 each [2]. - Each Class A Unit includes one share of common stock and one common warrant, while each Class B Unit includes one pre-funded common stock purchase warrant and one common warrant [2]. - The common warrants have an exercise price of $5.25 per share and are exercisable upon issuance for a term of five years [2]. Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, including working capital and operating expenses, as well as to initiate a Phase 1b clinical study of CLR 121125 in triple-negative breast cancer [4]. Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on developing proprietary drugs for cancer treatment, leveraging its Phospholipid Drug Conjugate™ delivery platform to enhance treatment efficacy and safety [7].